Bristol Myers Squibb Australia Riders Raise More Than $40,000 for Rare Cancers Australia Through C2C4C Asia Pacific

Australia's Largest-Ever Team Has More Than Doubled Its Original Fundraising Target to Support Australians Facing a Rare Cancer

(MELBOURNE, Australia, 6 November 2026) – Bristol Myers Squibb Australia's (BMSA's) C2C4C team has raised more than $40,000 AUD for Rare Cancers Australia (RCA), more than doubling its original goal of $17,000. The funds were raised by nine Bristol Myers Squibb Australia employees who took part in C2C4C (Continent 2 Continent 4 Cancer) Asia Pacific, a 15-day cycling event in Japan for cancer research. The funds will support RCA's work to ensure that no Australian facing a rare cancer has to navigate their journey alone.

From 6–20 October, the Australian riders – the largest Bristol Myers Squibb Australia team to take part in the event – joined more than 55 colleagues from seven markets (including China, India, Japan and Singapore) to ride nearly 1,800 kilometres from Tokyo Bay to Otemachi, Tokyo, after months of training alongside their day-to-day responsibilities. Along the way, they tackled long days in the saddle and challenging terrain, all while staying focused on their cause.

"Our riders have shown what is possible when a team comes together for a cause that matters. To more than double our fundraising goal is an incredible achievement. It is a credit to our team's commitment and to the generosity of everyone who backed us. I would like to thank each and every one of our supporters for choosing to make a difference," said Natasha Woodward, Associate Director, Business Risk Management and Compliance at BMSA.

Every year, 42,000 Australians are diagnosed with a rare cancer. RCA works to ensure that Australians battling a rare cancer have access to the support, advocacy and connection they need.

"In Australia, rare and less common cancers account for one in four cancer diagnoses. Partnerships like this help shine a light on the unique challenges faced by people living with a rare cancer, while allowing Rare Cancers Australia to help patients and families when they need it most," said Christine Cockburn, Chief Executive Officer at Rare Cancers Australia.

"While the riders rode as one team, each was motivated by their own personal connection to the cause. Some rode in honour of loved ones, while others were inspired by patients and families whose lives have been touched by cancer," said Owen Smith, General Manager Bristol Myers Squibb Australia and New Zealand.

"I started riding in memory of my uncle, who passed away from a rare cancer last year. On the hardest climbs I carried a small painted rock made by a young cancer patient, a reminder of why we were there. I had the choice to stop. People facing cancer don't. What I'll remember most is the kindness of colleagues from around the world, who cheered each other up every hill," said Ngan Huynh, Senior Manager, Medical Strategy & Operations Lead at BMSA.

The Bristol Myers Squibb Australia riders were Alain Ekanayake, Anna Kirkpatrick, Brad Cox, Ken Roberts, Marcel Hemme, Natasha Woodward, Ngan Huynh, Steeve Florent and Suzanne McLay.

The Australian team's efforts form part of the global C2C4C initiative. For the 13th consecutive year, Bristol Myers Squibb employees have come together to ride across four continents in support of cancer organisations, with more than 300 riders representing 33 countries covering over 9,000 kilometres to support more than 25 local cancer charities. Since 2014, more than $21 million USD has been donated globally for cancer research, including more than $830,000 USD donated via the C2C4C Asia Pacific ride since 2021.

Bristol Myers Squibb Australia thanks everyone who supported the team along the way.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.

For further information:

Bristol Myers Squibb Australia & New Zealand
Alison Melville, Associate Director Corporate Affairs
alison.melville@bms.com
PH: 0477 309 012

###